Clinical Trials Logo

Psychotic Depression clinical trials

View clinical trials related to Psychotic Depression.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02782442 Completed - Schizophrenia Clinical Trials

Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM)

Start date: September 1, 2016
Phase: N/A
Study type: Interventional

Primary study: This study is a single-site, double-blind, randomized, controlled clinical trial to compare an evidence-based structured program of 30-35 hours of on-line cognitive and social cognitive training exercises performed over 16 weeks (~2 hours per week), delivered with an innovative digital app which provides users with a motivation coach to set personalized goals and with secure social networking for peer support, "PRIME" ; vs. 2) A control condition of computer games, encouraged at ~2 hours per week over 16 weeks, delivered with "PRIME". Unblinded Cognitive Training Sub-Study: Participants who were randomized to the computer games arm of the trial may be offered access to the active cognitive training at the end of their 6 month follow up appointments, if they still meet inclusion criteria. PRIME Super Users Sub-Study: Participants who have provided all follow up data to the initial study, including those who are currently enrolled in the Unblinded Cognitive Training sub-study, may be offered continued participation in the PRIME community as super-users.

NCT ID: NCT01427608 Completed - Clinical trials for Psychotic Depression

Sustaining Remission of Psychotic Depression

STOP-PD
Start date: October 2011
Phase: Phase 4
Study type: Interventional

The acute phase of this study will monitor the response to a combination of an atypical antipsychotic medication olanzapine with an antidepressant medication sertraline in the acute treatment of the disorder. It is predicted that this combination will improve symptoms of psychotic depression and be associated metabolic side effects. Factors that moderate tolerability will be monitored. Improvement in symptoms could take between 4 and 12 weeks, followed by a period of 8 weeks during which participants will continue to take the same medications to stabilize the remission from symptoms of psychotic depression. The maintenance phase will be a randomized, double-blind, placebo-controlled study of olanzapine for a period of up to 36 weeks to test whether continuing this combination decreases the risk of relapse and whether discontinuing the combination leads to improvement in metabolic measures. Subjects who complete the acute phase will be asked to consent separately to the randomized maintenance phase.

NCT ID: NCT00751504 Completed - Clinical trials for Psychotic Depression

Quetiapine in the Treatment of Psychotic Depression - a Pilot Study

Start date: September 2008
Phase: Phase 3
Study type: Interventional

Atypical antipsychotics have been found not only to be beneficial in the treatment of psychotic disorders, but even for depressive symptoms in patients with schizophrenia. Remarkably, preliminary data suggest that the atypical antipsychotic quetiapine has antidepressive properties. Until now, there is limited knowledge concerning the efficacy of quetiapine in major depressive illness and especially in psychotic depression. In our own clinical practice, several patients with psychotic depression were successfully treated with quetiapine as add-on therapy or as monotherapy. On the background of that, the convincing effects of quetiapine in bipolar depression, single-case reports and pilot studies concerning its effectiveness in depressive mood states in psychotic disorders as well as our clinical experiences, it is to assume that a treatment with quetiapine over a 6 weeks period show similar effects in major depressive episode with psychotic features, i.e. psychotic depression. In this pilot study we plan to investigate 20 patients with psychotic features of depression under treatment with quetiapine.

NCT ID: NCT00556140 Completed - Clinical trials for Psychotic Depression

The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression

Abilify
Start date: June 2003
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.

NCT ID: NCT00400166 Completed - Schizophrenia Clinical Trials

Recovery Guide Intervention for Recurrent Psychiatric Hospitalization

Start date: December 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether Recovery Guide support services are effective in promoting recovery and social integration among psychiatrically disabled individuals who experience high rates of inpatient hospitalizations.